Quantifying human health risks from animal antimicrobials

Interfaces

Volumn 37, Issue 1, 2007, Pages 22-38

  Cox Jr , Louis Anthony ^a   Popken, Douglas A ^a   Carnevale, Richard ^b  

^a Cox Associates ^*  (United States)

^b Animal Health Institute   (United States)

Author keywords

Decision analysis: risk; Health care: epidemiology

Indexed keywords

EID: 34247613222     PISSN: 00922102     EISSN: 1526551X     Source Type: Journal    
DOI: 10.1287/inte.1060.0275     Document Type: Review

References (66)

1. American Hospital Association (AHA). 2001. Hospital Statistics. Health Forum, American Hospital Association, Chicago, IL.
2. Angulo, F. J., V. N. Nargund, T. C. Chiller. 2004. Evidence of an association between use of anti-microbial agents in food animals and anti-microbial resistance among bacteria isolated from humans and the human health consequences of such resistance. J. Vet Med. B Infectious Disease Vet. Public Health 51(8-9) 374-379.
3. Austin, D. J., M. J. M. Bonten, R. A. Weinstein, S. Slaughter, R. M. Anderson. 1999. Vancomycin-resistant enterococci in intensivecare hospital settings: Transmission dynamics, persistence, and the impact of infection control programs. Proc. National Acad. Sci. USA 96 6908-6913.
4. Bafundo, K. 2004. What to expect from the inclusion or deletion of growth promoting antibiotics in animal feeds: Effects in animals and in man. Animal Feed Manufacturers Association (AFMA) Forum, March 10-12, Sun City, North-west Province, South Africa. http://www.afma.co.za/AFMA_Template/feedpaper2.html.
5. Bafundo, K., L. A. Cox Jr. 2002. Human health risk from use of virginiamycin in chickens. Presented at 37th National Meeting on Poultry Health and Processing, Oct. 9-11, Ocean City, MD. http://www.poultryegg.org/SPSS/vacc/ fullscreen.htm. Summarized in The Poultry Informed Professional, Vol. 67, Department of Avian Medicine, University of Georgia, Athens, GA. http://www. avian. uga. edu/documents/pip/2002/1102.pdf.
6. Barza, M., K. Travers. 2002. Excess infections due to antimicrobial resistance: The "attributable fraction." Clinical Infectious Diseases 34(Suppl. 3) S126-S130.
7. Buzby, J. C., T. Roberts, C. T. Jordan Lin, J. M. MacDonald. 1996. Bacterial foodborne disease: Medical costs and productivity losses. US Department of Agriculture, Economic Research Service, Agricultural Economics, Report # 741. http://www.ers.usda.gov/publications/aer741/.
8. Casewell, M., C. Friis, E. Marco, P. McMullin, I. Phillips. 2003. The European ban on growth-promoting antibiotics and emerging consequences for human and animal health. J. Antimicrobial Chemotherapy 52(2) 159-161.
9. Centers for Disease Control and Prevention (CDC). 2005. Preliminary FoodNet data on the incidence of infection with pathogens transmitted commonly through food - 10 sites, United States. 2004. Morbidity Mortality Weekly Report 54(14) 352-356.
10. Cervantes, H. 2005. Assessing the results of the EU ban on antibiotic feed additives. ThePigSite.com, feature article. http://www. thepigsite.com/FeaturedArticle/Default.asp?Display=1509.
11. Clark, N. C., R. C. Cooksey, B. C. Hill, J. M. Swenson, F. C. Tenover. 1993. Characterization of glycopeptide-resistant enterococci from U.S. hospitals. J. Antimicrobial Agents Chemotherapy 37(11) 2311-2317.
12. Cox, L. A., Jr. 2002. Reexamining the causes of campylobacteriosis. Internat. J. Infectious Diseases 6(Suppl. 3) S26-S36.
13. Cox, L. A., Jr. 2005. Potential human health benefits of antibiotics used in food animals: A case study of virginiamycin. Environment Internat. 31(4) 549-563.
14. Cox, L. A., Jr. 2006. Quantitative Health Risk Analysis Methods: Modeling the Human Health Impacts of Antibiotics Used in Food Animals. Springer, New York.
15. Cox, L. A., Jr., D. A. Popken. 2002. A simulation model of human health risks from chicken-borne Campylobacter jejuni. Technology 9(1-2) 55-84.
16. Cox, L. A., Jr., D. A. Popken. 2004a. Bayesian Monte Carlo uncertainty analysis of human health risks from animal antimicrobial use in a dynamic model of emerging resistance. Risk Anal. 24(5) 1153-1164.
17. Cox, L. A., Jr., D. A. Popken. 2004b. Quantifying human health risks from virginiamycin used in chickens. Risk Anal 24(1) 271-288.
18. Cox, L. A., Jr., D. A. Popken. 2006. Quantifying potential human health impacts of animal antibiotic use: Enrofloxacin and macrolides in chickens. Risk Anal. 26(1) 135-146.
19. Cox, L. A., Jr., D. Babayev, W. Huber. 2005. Some limitations of qualitative risk rating systems. Risk Anal. 25(3) 651-662.
20. Critchley, I. A., R. S. Blosser-Middleton, M. E. Jones, C. Thornsberry, D. F. Sahm, J. A. Karlowsky. 2003. Baseline study to determine in vitro activities of daptomycin against gram-positive pathogens isolated in the United States in 2000-2001. Antimicrobial Agents Chemotherapy 47(5) 1689-1693.
21. Cromwell, G. L. 2002. Why and how antibiotics are used in swine production. Animal Biotechnology 13(1) 7-27.
22. Cummings, T. S. 2006. Stakeholder position paper: Poultry. Prev Vet. Med. 73(2-3) 209-212.
23. Danish Integrated Antimicrobial Resistance Monitoring and Research Programme (DANMAP). 2004. Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, foods and humans in Denmark, http://www.dfvf.dk/default.asp?ID=9604.
24. Danish Zoonosecenter. 2001. Annual reports on Zoonoses in Denmark 1997-2000. http://zoonyt.dzc.dk.
25. ElAmin, A. 2006. Foodborne Campylobacter infections increase. Foodproductiondaily.com. Retrieved January 3, 2006. http://www. foodproductiondaily.com/news/ng.asp?id=64828.
26. Eliopoulos, G. M., C. B. Wennersten, H. S. Gold, T. Schulin, M. Soull, M. G. Farris, S. Cerwinka, H. L. Nadler, M. Dowzicky, G. H. Talbot, R. C. Moellering Jr. 1998. Characterization of vancomycin resistant enteroccocus faecium isolates from the United States and their susceptibility in-vitro to dalfopristin-quinupristin. Antimicrobial Agents Chemotherapy 42(5) 1088-1092.
27. European Food Safety Authority (EFSA). 2006. Trends and sources of zoonoses, zoonotic agents and antimicrobial resistance in the European Union in 2004. http://www.efsa.europa.eu/en/publications/scientific.html.
28. European Union (EU). 2000. Communication from the Commission on the Precautionary Principle. Report COM (2000) 1, Commission of the European Communities, Brussels, Belgium, 2/2/2000. http://ec.europa.eu/comm/dgs/ health_consumer/library/pub/pub07_en.pdf.
29. Eurosurveillance. 2002. Campylobacteriosis in Norway 2001: Incidence still rising. Eurosurveillance Weekly 6(24) http://www. eurosurveillance.org/ew/2002/020613.asp.
30. Eurosurveillance. 2005. Trends in zoonoses in Europe 2003. Eurosurveillance Weekly 10(5) 26. http://www.eurosurveillance. org/ew/2005/050526.asp.
31. Harder, B. 2002. Put out to pasture: Strategy to prolong antibiotics' potency. Sci. News 161(17). http://www.keepantibioticsworking.com/ new/news.cfm?RefID=36667.
32. Hayes, D. J., H. H. Jensen. 2003. Lessons from the Danish ban on feed-grade antibiotics. Choices Magazine (third quarter), http://www.choicesmagazine.org/2003-3/2003-3-01.pdf.
33. Hershberger, E., S. F. Oprea, S. M. Donabedian, M. Perri, P. Bozigar, P. Bartlett, M. J. Zervos. 2005. Epidemiology of antimicrobial resistance in enterococci of animal origin. J. Antimicrobial Chemotherapy 55(1) 127-130.
34. Hurd, H. S. 2005. Can antibiotic use in food animals actually reduce consumer risk? Food Safety Asia 2 120-122. http://www. gdspublishing.com/ic_pdf/fsa/phib.pdf.
35. Institute for Agriculture and Trade Policy (IATP). 2004. PDA: Use of virginiamycin in animals no significant threat to human health. Ag Observatory (Dec. 27). http://www.agobservatory.org/headlines.cfm?refID= 37706.
36. Jones, R. N., T. R. Pritsche, H. S. Sader, B. P. Goldstein. 2005. Antimicrobial spectrum and potency of dalbavancin tested against clinical isolates from Europe and North America (2003): Initial results from an international surveillance protocol. J. Chemotherapy 17(6) 593-600.
37. Jones, R. N., H. S. Sader, M. E. Erwin, S. A. Anderson, Enterococcus Study Group. 1995. Emerging multiply resistant enterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance study in the United States. Diagnostic Microbiology Infectious Disease 21(2) 85-93.
38. Jones, R. N., C. H. Ballow, J. Acar, A. Fluit, H. S. Sader, J. Turnidge, J. Deinhart, D. J. Biedenbach. 1999. World-wide evaluation of quinupristin/qalfopristin (Q/D; Synercid) antimicrobial activity directed against resistant gram-positive pathogens: Report from global SMART study. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA. http://www.ket-on-line.com/icaac/Posters/Jones. pdf.
39. KeepMedia. 2005. World-leading pork exporter Denmark sees sharp increase in pig mortality, www.keepmedia.com/ShowItemDetails.do?itemID=991278&extID= 10030.
40. Lawton, R. M., S. K. Fridkin, R. P. Gaynes, J. E. McGowan Jr. 2000. Practices to improve antimicrobial use at 47 US hospitals: The status of the 1997 SHEA/IDSA position paper recommendations. Infection Control and Hospital Epidemiology 21(4) 256-259.
41. Linden, P. K. 2002. Treatment options for vancomycin-resistant enterococcal infections. Drugs 62(3) 425-441.
42. Linden, P. K., A. W. Pasculle, D. McDevitt, D. J. Kramer. 1997. Effect of quinupristin/dalfopristin on the outcome of vancomycinresistant Enterococcus faecium bacteraemia: Comparison with a control cohort. J. Antimicrobial Chemotherapy 39(Suppl. A) 145-151.
43. Marano, N., D. Vugia, T. Fiorentino, S. Segler, M. Carter, H. Kassenborg, K. Smith, S. Sansky, K. Hollinger, F. Angulo, EIP FoodNet Working Group. 2000. Fluoroquinolone-resistant Campylobacter causes longer duration of diarrhea than fluoroquinolone-susceptible Campylobacter strains in FoodNet sites. International Conference on Emerging Infectious Diseases, Atlanta, GA. Synopsis www.cdc.gov/foodnet/pub/publications/2000/marano_ 2000. pdf.
44. McDermott, P. F., S. Zhao, D. D. Wagner, S. Simjee, R. D. Walker, D. G. White. 2002. The food safety perspective of antibiotic resistance. Animal Biotechnology 13(1) 71-84.
45. Moellering, R. C., P. K. Linden, J. Reinhardt, E. A. Blumberg, F. Bompart, G. H. Talbot. 1999. The efficacy and safety of quinupristin- dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. J. Antimicrobial Chemotherapy 44(2) 251-261.
46. National Academies of Science (NAS). 1999. The Use of Drugs in Food Animals: Benefits and Risks. National Academies Press, Washington, D.C.
47. National Nosocomial Infections Surveillance (NNIS). 2001. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992-June 2001, issued August 2001. Amer. J. Infection Control 29 404-421.
48. National Research Council. 1998. The use of drugs in food animals: Benefits and risks. National Research Council and the Institute of Medicine Report, National Research Council, Washington, D.C.
49. Patrick, M. E., L. E. Christiansen, M. Waino, S. Ethelberg, H. Madsen, H. C. Wegener. 2004. Effects of climate on incidence of Campylobacter spp. in humans and prevalence in broiler flocks in Denmark. Appl. Environmental Microbiology 70(12) 74-80.
50. Pugh, D. M. 2002. The EU precautionary bans of animal feed additive antibiotics. Toxicology Letters 128(1-3) 35-44.
51. Russell, S. M. 2003. The effect of airsacculitis on bird weights, uniformity, fecal contamination, processing errors, and populations of Campylobacter spp. and escherichia coli. Poultry Sci. 82(8) 1326-1331.
52. Samuel, M. C., D. J. Vugia, S. Shallow, R. Marcus, S. Segler, T. McGivern, H. Kassenborg, K. Reilly, M. Kennedy, F. Angulo, R. V. Tauxe, Emerging Infections Program FoodNet Working Group. 2004. Epidemiology of sporadic Campylobacter infection in the United States and declining trend in incidence, FoodNet 1996-1999. Clinical Infectious Diseases 38(Suppl. 3) S165-S174.
53. Shnayerson, M., M. J. Plotkin. 2002. The Killers Within: The Deadly Rise of Drug-Resistant Bacteria. Little, Brown and Company, Boston, MA.
54. Shryock, T. 2003. Antibiotic resistance: A global perspective. Paper presented at American Meat Institute trade show, Nashville, TN. www.meatami.com/Content/TradeShow/ConferenceMaterials/2004Mirc/Tom%20Shryock. pdf.
55. Snary, E. L., L. A. Kelly, H. C. Davison, C. J. Teale, M. Wooldridge. 2004. Antimicrobial resistance: A microbial risk assessment perspective. /. Antimicrobial Chemotherapy 53(6) 906-917.
56. State of New Jersey (SNJ). 2000. Epidemiology surveillance system 1998 report. New Jersey Department of Health and Senior Services, Division of Epidemiology, Environmental and Occupational Health, http://www.state.nj.us/ health/cd/ess1998.
57. Stern, N. J., M. C. Robach. 2003. Enumeration of Campylobacter spp. in broiler feces and in corresponding processed carcasses. /. Food Protection 66(9) 1557-1563.
58. Swann, M. M. 1969. Report of the Joint Committee on the Use of Antibiotics in Animal Husbandry and Veterinary Medicine, Her Majesty's Stationary Office, London, UK.
59. Thal, L. A., S. Donabedian, B. Robinson-Dunn, J. W. Chow, L. Dembry, D. B. Clewell, D. Alshab, M. J. Zervos. 1998. Molecular analysis of glycopeptide-resistant enterococcus faecium isolates collected from Michigan hospitals over a 6-year period. J. Clinical Microbiology 36(11) 3303-3308.
60. US Food and Drug Administration, Center for Veterinary Medicine (FDA-CVM). 2004. Draft risk assessment of streptogramin resistance in enterococcus faecium attributable to the use of streptogramins in animals. November 23. Rockville, MD.
61. Webb, M., L. W. Riley, R. B. Roberts. 2001. Cost of hospitalization for and risk factors associated with vancomycin resistant Enterococcus faecium infection and colonization. Clinical Infectious Diseases 33(4) 445-452.
62. Wegener, H. C. 2003. Antibiotics in animal feed and their role in resistance development. Curr. Opin. Microbiol. 6(5) 439-445.
63. Willems, R. J., W. Homan, J. Top, M. van Santen-Verheuvel, D. Tribe, X. Manzioros, C. Gaillard, C. M. Vandenbroucke-Grauls, E. M. Mascini, E. van Kregten, J. D. van Embden, M. J. Bonten. 2001. Variant esp gene as a marker of a distinct genetic lineage of vancomycin-resistant enterococcus faecium spreading in hospitals. Lancet 357(9259) 853-855.
64. Willems, R. J. L., J. Top, N. van den Braak, A. van Belkum, H. Endtz, D. Mevius, E. Stobberingh, A. van den Bogaard, J. D. A. van Embden. 2000. Host specificity of vancomycin-resistant enterococcus faecium. J. Infectious Diseases 182(3) 816-823.
65. World Health Organization (WHO). 2003a. Joint FAO/OIE/WHO Expert Workshop on Non-Human Antimicrobial Usage and Antimicrobial Resistance: Scientific Assessment. Geneva, Switzerland, December 1-5. http://www.who.ints/foodsafety/ publications/micro/en/amr.pdf.
66. World Health Organization (WHO). 2003b. Background document for the joint WHO/FAO/OIE Expert Workshop on Non-Human Antimicrobial Usage and Antimicrobial Resistance: Scientific Assessment. Geneva, Switzerland, Dec. 1-5. http://www.who.int/foodsafety/publications/micro/en/background, pdf.